Advertisement
 
News
Subscribe to Drug Discovery & Development News

The Lead

Celgene Snags New Crohn's Disease Drug

April 24, 2014 | Comments

Celgene Corp. entered into a global license agreement with Nogra Pharma Ltd. to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease. Read more...  

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Kala Advances Trials of Eye Drugs with $22.5M Financing

April 24, 2014 3:07 pm | Comments

Kala Pharmaceutical Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, announced it has completed a $22.5 million Series B financing. Read more...  

TOPICS:

U.S. Patent and Trademark Office Grants Allowance for Cancer Drugs

April 24, 2014 2:49 pm | Comments

Epizyme Inc., a clinical stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application No. 13/722,807 with claims that cover methods of treating cancer with EZH2 inhibitors. Read more...

TOPICS:

Celsion Updates Survival Data for Liver Cancer Drug

April 24, 2014 2:39 pm | Comments

Celsion Corporation announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase 3 OPTIMA Study, were presented at the 5th European Conference on Interventional Oncology (ECIO) on Thursday in Berlin, Germany. Read more...

TOPICS:
Advertisement

FDA Approves First Castleman’s Disease Drug

April 24, 2014 2:19 pm | Comments

Janssen Biotech Inc. announced the U.S. Food and Drug Administration (FDA) has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Read more...

TOPICS:

Researchers Find New HIV Target

April 24, 2014 2:05 pm | Comments

Scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) have discovered a new vulnerable site on HIV that antibodies can attack to prevent infection from a broad range of the virus' many variants. Read more...

TOPICS:

Eli Lilly Q1 Profit Tumbles 53%

April 24, 2014 1:45 pm | Comments

Eli Lilly's first-quarter earnings plunged 53% after the expiration of a key patent protecting its top-selling antidepressant cut into the drugmaker's revenue, and it lost protection for the osteoporosis treatment Evista. Read more...  

TOPICS:

Breaking News: Court Won't Reconsider Risperdal Case

April 24, 2014 12:59 pm | Comments

The Arkansas Supreme Court on Thursday declined to reconsider its decision that threw out a $1.2 billion judgment against a pharmaceutical company accused of improperly marketing an antipsychotic drug. Read more...           

TOPICS:

Lupin, Yoshindo Ink Joint Biosimilars Venture

April 24, 2014 10:39 am | Comments

Lupin Ltd. announced that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. to create a new entity, YL Biologics (YLB). Read more...             

TOPICS:
Advertisement

Sinovac Wins China Government Grant for HFMD Vaccine

April 24, 2014 10:28 am | Comments

Sinovac Biotech Ltd. announced that it has received a government grant in China for construction of the company’s dedicated production facility for its Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Read more...    

TOPICS:

Germany's Merck Posts Positive PKU Drug Results

April 24, 2014 10:12 am | Comments

Merck announced that the Phase 3b SPARK study has met its primary endpoint in children less than 4 years of age who have phenylketonuria (PKU). Read more...                            

TOPICS:

AMSBIO Expands U.S. Operations

April 23, 2014 12:58 pm | Comments

AMSBIO has announced the opening of a new North American headquarters with executive management facilities in Cambridge, Mass., for its U.S. subsidiary, AMSBIO LLC, recognized  as a leading company contributing to the acceleration of discovery. Read more...

TOPICS:

FDA Clears IND Amendment for Hematologic Cancer Drug

April 23, 2014 12:40 pm | Comments

Fate Therapeutics Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced that the FDA has cleared its IND amendment to evaluate Prohema in pediatric patients undergoing hematopoietic stem cell transplantation for hematologic malignancies. Read more...

TOPICS:

Glaucoma Adjunct Restores Vision in Blinding Disorder

April 23, 2014 12:25 pm | Comments

An inexpensive glaucoma drug, acetazolamide, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health. Read more...

TOPICS:

Bayer's Ciprofloxacin DPI Gets Orphan Drug Status

April 23, 2014 11:41 am | Comments

Bayer HealthCare announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis. Read more...

TOPICS:

Lpath, Walter Reed Collaborate on Brain Injury Drug

April 23, 2014 11:23 am | Comments

Lpath Inc., the industry leader in bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading